Amicrobe

Amicrobe, which operates under the brand name Macro Biologics, is a privately held biotechnology company headquartered in Carlsbad, California, in the United States. The company designs, patents, and produces advanced biomaterials intended for safer healthcare, clean food and water, and better packaging. Its work sits at the interface of materials science, biotechnology, and advanced manufacturing. Macro Biologics' first and most advanced class of products is the Amicidins™, a family of investigational biological therapeutics designed to prevent and treat infection. The company's initial focus is surgery and trauma, where infection is understood as a progression that is best stopped early. Dangerous microbes reach vulnerable tissues through gateways such as surgical and traumatic wounds, the throat and upper airway, and the urinary tract. A focal infection, such as a surgical site infection or pneumonia, can then lead to sepsis. Macro Biologics' strategy is to guard those gateways with Amicidins in at-risk patients, with the goal of stopping infections before they become life-threatening. The company's two lead investigational products are Amicidin-α Surgical and Amicidin-β Solution, which are described as broadly covering all wound classifications of surgery and trauma and as designed for use in operating rooms and other controlled settings. Both are intended to become first-in-class breakthrough biological therapeutics for the prevention and treatment of infection in surgery and trauma. In response to requests for additional products for special settings, Macro Biologics is also developing Amicidin-α PFC (Prolonged Field Care) for military use with support from the U.S. Department of Defense, and Amicidin-β/EF (Extended Formulation) for traumatic wounds and emergency cesarean delivery, including in low- and middle-income countries, with support from the Global AMR Innovation Fund (GAMRIF) and CARB-X. Macro Biologics' pipeline has attracted support from a range of public and philanthropic funders. Its work has been supported by the U.S. Army Medical Research & Materiel Command through the Military Burn Research Program and by the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Medical Research Program. Ongoing support comes from CARB-X, provided by the Department of Health & Human Services Assistant Secretary for Preparedness & Response (BARDA), the Wellcome Trust, and the UK Secretary of State for Health and Social Care (DHSC) through a Boston University subaward, as well as by the U.S. Army Medical Research & Materiel Command through the Medical Technology Enterprise Consortium. The company also positions itself as a partner for organizations seeking to create new products or improve existing ones. Amicrobe is a private company and does not appear to be listed on a public stock exchange. Its headquarters in Carlsbad, California, places it within one of the United States' prominent life sciences and biotechnology clusters. The company's public communications emphasize a mission of developing biomaterials and biologics that address infection and antimicrobial resistance, a global health challenge that has drawn increasing attention from governments, foundations, and multilateral bodies.

Amicrobe is a biotechnology company based in Carlsbad, California, in the United States. Public information about the company's founding and early history is limited, but its current operations are conducted under the brand name Macro Biologics. The company describes itself as operating at the interface of materials science, biotechnology, and advanced manufacturing, designing, patenting, and producing advanced biomaterials for safer healthcare, clean food and water, and better packaging. Macro Biologics' first and most developed product class is the Amicidins™, a family of investigational biological therapeutics. The company's initial focus is surgery and trauma. Its rationale is that infection is a progression best stopped early: dangerous microbes reach vulnerable tissues through gateways such as surgical and traumatic wounds, the throat and upper airway, and the urinary tract. A focal infection, such as a surgical site infection or pneumonia, can then progress to sepsis. The company's strategy is to guard those gateways with Amicidins in at-risk patients, with the aim of stopping infections before they become life-threatening. The company's two lead investigational products are Amicidin-α Surgical and Amicidin-β Solution. According to the company, these broadly cover all wound classifications of surgery and trauma and are designed for use in operating rooms and other controlled settings. Both are intended to become first-in-class breakthrough biological therapeutics for the prevention and treatment of infection in surgery and trauma. In response to requests for additional products designed for special settings, Macro Biologics is also developing Amicidin-α PFC (Prolonged Field Care) for military use, with support from the U.S. Department of Defense, and Amicidin-β/EF (Extended Formulation) for traumatic wounds and emergency cesarean delivery, including in low- and middle-income countries, with support from the Global AMR Innovation Fund (GAMRIF) and CARB-X. The company's research has received support from a range of public and philanthropic funders. Its work has been supported by the U.S. Army Medical Research & Materiel Command through the Military Burn Research Program under Award No. W81XWH-15-2-0065 and by the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Medical Research Program under Award No. W81XWH-16-1-0561. Ongoing support comes from CARB-X, provided by the Department of Health & Human Services Assistant Secretary for Preparedness & Response (BARDA), the Wellcome Trust, and the UK Secretary of State for Health and Social Care (DHSC) through Boston University subaward 4500004446, as well as by the U.S. Army Medical Research & Materiel Command through the Medical Technology Enterprise Consortium under Award No. MTEC-21-03-WI-021. The company also invites partners to work with it to create new products and improve existing ones. Amicrobe is a private company and does not appear to be listed on a public stock exchange. Its headquarters in Carlsbad, California, places it within a significant life sciences and biotechnology cluster in the United States. The company's public communications emphasize a mission of developing biomaterials and biologics that address infection and antimicrobial resistance, a global health challenge that has drawn increasing attention from governments, foundations, and multilateral bodies.

• Supported by US Army Medical Research & Materiel Command through the Military Burn Research Program under Award No. W81XWH-15-2-0065.

• Supported by the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Medical Research Program under Award No. W81XWH-16-1-0561.

• Ongoing support from CARB-X, provided by BARDA, Wellcome Trust, and UK DHSC through Boston University subaward 4500004446.

• Supported by the U.S. Army Medical Research & Materiel Command through the Medical Technology Enterprise Consortium under Award No. MTEC-21-03-WI-021.

A biotechnology company developing first-in-class Amicidin™ biologics and advanced biomaterials to prevent and treat infection in surgery, trauma, and other healthcare settings, with support from major U.S. and international defense and health funders.

• Amicidins™

  First class of investigational biological therapeutics designed to prevent and treat infection.

• Amicidin-α Surgical

  Lead investigational product designed for use in operating rooms and other controlled settings, broadly covering all wound classifications of surgery and trauma.

• Amicidin-β Solution

  Lead investigational product designed for use in operating rooms and other controlled settings, broadly covering all wound classifications of surgery and trauma.

• Amicidin-α PFC (Prolonged Field Care)

  Product in development for military use, with support from the U.S. Department of Defense.

• Amicidin-β/EF (Extended Formulation)

  Product in development for traumatic wounds and emergency cesarean delivery, including in low- and middle-income countries, with support from GAMRIF and CARB-X.

1. 1Macro Biologicsmacrobiologics.com
2. 2PIPELINE | Macro Biologicsmacrobiologics.com
3. 3Amicrobe (United States) - Wikidatawikidata.org